Skip to main content

Newsroom press releases

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)
Financial Data
Download

28/04/25 - 16:50

Shareholders' Meeting 2025 (138.81 KB)
Other
Download

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
Products
Download

07/04/25 - 13:07

Publication of the lists of candidates for the appointment of the Board Directors, the Board of Statutory Auditors and relevant proposals for resolution. (111.09 KB)
Financial Disclosures
Download

04/04/25 - 0:59

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)
Other
Download

31/03/25 - 19:36

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)
Other
Download

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
Products Molecular
Download

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)
Financial Data
Download

03/03/25 - 21:19

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)
Other
Download

03/03/25 - 21:05

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)
Other
Download

28/02/25 - 11:49

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)
Other
Download

27/01/25 - 20:14

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)
Other
Download

16/12/14 - 1:00

FDA approves 1,25 Vitamin D in the US market (239.73 KB)
Products Immunodiagnostic
Download

09/12/14 - 1:00

DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)
Products Immunodiagnostic
Download

14/11/14 - 1:00

The Board of Directors approves the results for Q3'14 (785.42 KB)
Financial Data
Download

07/10/14 - 2:00

DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)
Products Immunodiagnostic
Download

18/09/14 - 2:00

DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)
Products Immunodiagnostic
Download

01/08/14 - 2:00

The Board of Directors approves the results for H1'14 (812.25 KB)
Financial Data
Download

22/07/14 - 2:00

DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)
Financial Data
Download

30/06/14 - 2:00

DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)
Products Immunodiagnostic
Download

03/06/14 - 2:00

DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)
Products Immunodiagnostic
Download

09/05/14 - 2:00

The Board of Directors approves the results for Q1'14 (573.05 KB)
Financial Data
Download

23/04/14 - 2:00

Shareholders' meeting approves FY Results 2013 (107.65 KB)
Financial Data
Download

06/03/14 - 1:00

The Board of Directors approves the results for FY'13 (753.73 KB)
Financial Data
Download

18/02/14 - 1:00

DiaSorin launches the new test for PTH on LIAISON (597.92 KB)
Products Immunodiagnostic
Download

11/02/14 - 1:00

DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)
Products Immunodiagnostic
Download

28/01/14 - 1:00

DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018 (336.26 KB)
Acquisition / Partnership
Download

24/01/14 - 1:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)
Products Immunodiagnostic
Download

09/01/14 - 1:00

DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)
Products Immunodiagnostic
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.